Here's why the Clinuvel (ASX:CUV) share price is pushing higher

The Clinuvel Pharmaceuticals Limited (ASX:CUV) share price is pushing higher on Thursday following the release of its Q3 update…

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is pushing higher on Thursday following the release of its third quarter update.

At the time of writing, the biopharmaceutical company's shares are up 1% to $30.22.

This latest gain means the Clinuvel share price is now up approximately 33% since the start of the year.

How did Clinuvel perform in the third quarter?

Clinuvel continued its positive form during the third quarter. For the three months ended 31 March, the company reported a 21% increase in cash receipts to $6.5 million. Net operating cash flows were $1.99 million for the quarter.

Management advised that this result reflects the increasing contribution from the commercial distribution of its SCENESSE (afamelanotide 16 mg) product in Europe and the United States.

SCENESSE is a treatment for adult patients with the rare genetic and metabolic condition, erythropoietic protoporphyria (EPP).

Positively, after the deferral of some orders or reduced order sizes during the outbreak of COVID-19 in Europe in 2020, the company notes that demand appears to have normalised. Even better, patient adherence to SCENESSE treatment remains very high.

Another positive that could be supporting the Clinuvel share price today is its growing footprint in the United States. The release explains that there are now 40 speciality centres that are trained and accredited to administer SCENESSE to EPP patients. This exceeds the 30 which originally had been planned.

Clinuvel's CFO, Darren Keamy, commented: "Our medical distribution model is effective in Europe and the US, which really needs to be seen against a challenging environment where lockdowns disrupt economic activity and the mobility of people."

"In alignment with our Strategic Updates, we focus on building the business through vertical integration of key functions to reach sustainability and self-reliance. As a result, the Company is controlling the increase of investments in a staged process to achieve these long-term goals."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Share Gainers

Why Bapcor, Ramelius, Sandfire, and WIA Gold shares are rising today

These shares are having a better day than most on Tuesday. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors started the week off in a good mood today.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Bellevue Gold, Bubs, Clarity Pharmaceuticals, and Regal Partners shares are rising today

These shares are starting the week on a positive note.

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Travel Shares

Guess which ASX All Ords travel stock just rocketed 17% on an earnings upgrade

Investors are piling into the ASX All Ords travel stock today. Here's what's happening.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »